December 2024 — The Australian Federal Government has delivered its official response to the 2023 Senate Inquiry into Attention-Deficit/Hyperactivity Disorder (ADHD), fully endorsing a critical recommendation to establish nationally consistent rules for prescribing ADHD medication.
The Inquiry’s report highlighted that the fragmented, state-by-state regulations for stimulant medication have created a “postcode lottery” of care, leading to massive financial burdens and long specialist waiting lists for the estimated one million Australians living with ADHD.
The government’s commitment to developing uniform prescribing rules is the only recommendation to receive its full support among the 15 recommendations put forth by the Senate Committee.
Key Takeaways from the Government Response:
National Consistency is Paramount: By fully supporting the call for a uniform prescribing framework, the government aims to remove a significant regulatory barrier. Currently, rules on who can diagnose and prescribe—and whether a patient can easily transfer care interstate—vary dramatically, often forcing patients to see expensive specialists for simple prescription refills that could be managed by a trained General Practitioner (GP).
Support-in-Principle for Other Reforms: The government also “supported in principle” nine other recommendations, including calls to review Medicare Benefits Schedule (MBS) items to reduce the financial burden of ADHD assessments, and acknowledging the need for increased GP involvement.
The Path Forward: Health organisations, including the Royal Australian College of General Practitioners (RACGP), have welcomed the move, stating that consistency is vital for patient equity and will help ease the severe pressure on the specialist health system. While a broader “National ADHD Framework” (a primary recommendation of the Inquiry) was only “noted” or “supported in principle,” the commitment to consistent prescribing is seen as the most immediate and impactful regulatory reform.